Skip to main content

Talk Bio

Search This Blog

Boehringer Ingelheim partners with Immunai on $15M AI‑driven T‑cell collaboration

on June 25, 2026

Get link
Facebook
X
Pinterest
Email
Other Apps

German drugmaker Boehringer Ingelheim has signed a multi‑project collaboration with AI‑driven biotech Immunai, initially worth up to $15 million through 2027

The deal focuses on decoding T‑cell dysfunction common to both cancer and autoimmune diseases

Immunai will use its single‑cell AI platform (AMICA‑OS) to analyze thousands of patient samples and then validate promising targets in its wet lab, with the goal of feeding new programs into Boehringer’s pipeline

Sources:

With $15M, BI becomes latest to buy into Immunai's AI platform

Immunai imports $215m in series B funding - Global Venturing

Immunai and AstraZeneca Expand AI-Driven Biomarker ...

Immunai signs up to $15 million research pact with Boehringer ...

Immunai Raises $60M to Reprogram Immunity

Andrii Buvailo, Ph.D.'s Post

Immunai - CTech

AstraZeneca in AI collaboration with Immunai to inform cancer drug trials

Meta Pharmaceuticals lands $15M to make autoimmune drugs with ...

Immunai announces a $215M Series B as its 'immune cell atlas ...

Immunai and Bristol Myers Squibb sign AI partnership

Israeli biotech startup Immunai raises $215m for drug ...

Fierce Biotech News & Reports

Advancing 'atlas' of immunology, Immunai raises $215M - BioCentury

Boehringer Ingelheim and IBM announce AI antibody drug discovery partnership - PMLiVE

AI platform Autoimmune Diseases Boehringer Ingelheim Collaboration Discover Immunai Malignant Neoplasms

Get link
Facebook
X
Pinterest
Email
Other Apps

Popular Posts

KOL Bulletin: Brilaroxazine's Potential Differentiation on EPS Over Risperidone in Schizophrenia

A leading US KOL states that brilaroxazine shows placebo-like extrapyramidal symptoms (EPS) at week 4, potentially differentiating it from risperidone which cannot achieve this 1 . Reviva plans to initiate the RECOVER-2 Phase 3 trial for brilaroxazine in schizophrenia in H1 2026 following FDA recommendation for additional efficacy and safety data 2 . Brilaroxazine demonstrates broad-spectrum efficacy across schizophrenia symptom domains, including negative symptoms, with a well-tolerated safety profile in over 900 subjects 2 4 . Phase 3 RECOVER trial data shows low EPS and akathisia, mild weight gain (1.52 kg pooled), reductions in prolactin levels, and improvements in sexual function over 1 year 4 . New publication highlights speech latency as an objective vocal biomarker for brilaroxazine's effect on negative symptoms, reinforcing efficacy 3 5 . Sources: 1. https://firstwordhealthtech.com 2. https://www.biospace.com/press-releases/reviva-announces-regulatory-update-...

Ultragenyx Resubmits BLA for UX111 Gene Therapy with New Long-Term Data for Sanfilippo Syndrome Type A

Ultragenyx resubmitted its Biologics License Application (BLA) to the FDA for UX111, an AAV9 gene therapy for Sanfilippo syndrome type A (MPS IIIA), including long-term clinical data on neurologic, biomarker, and safety improvements. 1 2 3 4 5 The resubmission addresses a Complete Response Letter from July 2025 related to manufacturing (CMC) observations and adds durable biomarker reductions, such as CSF heparan sulfate, with favorable safety profile. 2 4 5 FDA's six-month priority review has begun; PDUFA action date expected in Q3 2026. 2 4 5 If approved, UX111 would be the first therapy for this fatal pediatric neurodegenerative disorder. 1 3 4 5 New long-term data announced February 3, 2026, shows substantial biomarker improvements and functional benefits vs. natural history, consistent across age and severity. 2 Sources: 1. https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rare/ultragenyx-pharmaceutical/news/ultragenyx-bla-resubmission-puts-ux111-and-ra...

Pfizer's Monthly GLP-1 Data from VESPER-3: Competitive Weight Loss Validates $10B Metsera Acquisition

Pfizer's Phase 2b VESPER-3 trial of ultra-long-acting GLP-1 RA PF-08653944 (MET-097i) achieved up to 12.3% placebo-adjusted weight loss at 28 weeks with monthly maintenance dosing after initial weekly titration 1 3 4 . Weight loss continued robustly post-switch to monthly dosing with no plateau observed at week 28, supporting Phase 3 advancement including higher 9.6 mg dose 1 3 . Data described as competitive with rivals (9-13% at week 28), validating Pfizer's $10B Metsera acquisition, with 10 Phase 3 trials planned for 2026 1 3 2 . Tolerability profile favorable with mostly mild/moderate GI events; full VESPER-3 data to be presented June 2026 1 3 . Analysts view results as encouraging but note questions on placebo benefits, discontinuations, and comparison to prior weekly data 3 5 . Sources: 1. https://www.pfizer.com/news/press-release/press-release-detail/pfizers-ultra-long-acting-injectable-glp-1-ra-shows-robust 2. https://www.pharmaceutical-technology.com/anal...

Powered by Blogger

X-Data LLC